PDCD1 and renal cell adenocarcinoma: Several monoclonal antibodies targeting PD-1 (pembrolizumab, nivolumab, and cemiplimab) or PD-L1 (durvalumab, atezolizumab, and avelumab) for the treatment of hematological and solid malignancies have been approved by the Food and Drug Administration (FDA) [3], including treatments for metastatic melanoma, RCC, metastatic nonsmall cell lung cancer (NSCLC), classical Hodgkin’s lymphoma, metastatic urothelial carcinoma, and HCC [1].